Is Intralymphatic Allergen Immunotherapy Effective and Safe?
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
15 patients with moderate to severe allergic rhinitis against grass were recruited and
enrolled in the study. They received three open label intralympatic grass allergen injections
with the dose 1000 SQ-U each and with one month interval. The next year the patients were
randomized double blind to an active or placebo booster injection of 1000 SQ-U before the
pollen season. Grass specific IgG4 levels were measured before and at various time ponts
after treatment.